Inside or Outside: How a Global Pharmaceutical Company Used Bespoke Research and Strategy Advisory to Decide Whether to Build an In-House Medical Animation Capability or Deepen Its Agency Partnerships

Medical animation is not a single market. It contains at least three distinct capability requirements that rarely sit comfortably in the same team: scientific accuracy at the molecular and cellular level, visual communication quality at the standard expected in premium healthcare media, and regulatory navigation experience in the specific therapeutic areas where claims about mechanism of action are subject to close medical affairs scrutiny.

The client’s medical affairs leadership had been watching external animation spend grow and had drawn the natural conclusion that a portion of it was recoverable through in-house capability. What the procurement review had not examined was the composition of that spend, how much of it was high-frequency, relatively standardised content that an in-house team could handle, and how much was complex, therapeutically specific work where the agency’s scientific depth and regulatory experience were the primary value being purchased.

Building the wrong scope of in-house capability, either too broad and trying to replicate what specialist agencies had spent a decade developing, or too narrow to generate meaningful spend recovery, would produce a capital commitment that satisfied neither the procurement rationale nor the content quality the medical affairs team needed.

Key Challenges

• No bespoke research into the cost structure and capability requirements of in-house medical animation studios at comparable pharmaceutical companies.
• No assessment of the talent availability and timeline required to build a medical animation team with the scientific accuracy depth the content demanded.
• No analysis of whether the client’s content volume had crossed the in-house economics threshold.
• No structured breakdown of external spend by content complexity to identify which portion was genuinely recoverable in-house.
• A risk of over-scoping the in-house build and replicating agency depth in therapeutic areas at a cost the procurement rationale could not support.
• Medical affairs leadership pressure to produce a specific recommendation before the next operating plan committed the external animation budget for another cycle.

Pharmaceutical medical animation is one of the creative categories where the decision to bring capability in-house most frequently underestimates the depth of specialist knowledge the agency model is actually providing. The economic case for in-house can be real, but it applies to a specific subset of animation content, and knowing which subset requires understanding what the agency is actually doing that the procurement review is not capturing in its cost per asset calculation.